OTCMKTS:PHGUF Pharming Group (PHGUF) Stock Price, News & Analysis $1.11 0.00 (0.00%) As of 10/1/2026 Add Compare Share Share Stock Analysis Stock AnalysisChartEarningsNews and TrendsShort Interest About Pharming Group Stock (OTCMKTS:PHGUF) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Pharming Group alerts:Sign Up Key Stats Today's Range$1.11▼$1.1150-Day Range$1.10▼$1.3052-Week Range$1.10▼$2.17VolumeN/AAverage Volume50 shsMarket Capitalization$741.54 millionP/E Ratio92.08Dividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Pharming Group N.V. is a Netherlands-based biopharmaceutical company focused on developing and commercializing treatments for rare diseases. The company’s activities include research and development, regulatory approval, manufacturing, and global commercialization of medicines for patients with limited treatment options. Pharming’s principal product is Ruconest (conestat alfa), a recombinant C1 esterase inhibitor used to treat acute attacks of hereditary angioedema, a rare and potentially life-threatening genetic disorder. Ruconest is produced using Pharming’s proprietary transgenic production technology and is approved in several markets, including the United States and European Union. The company also markets Joenja (leniolisib), an oral treatment for activated phosphoinositide 3-kinase delta syndrome, or APDS. Joenja was approved in the United States in 2023 and is intended for patients aged 12 and older with this rare primary immunodeficiency. Pharming continues to evaluate opportunities to expand access to its products and advance additional therapies for rare diseases. Pharming was founded in 1988 and is headquartered in Leiden, the Netherlands. Its medicines are supplied to patients through commercial and distribution activities in multiple international markets. Sijmen de Vries has served as the company’s chief executive officer and executive director for much of its commercial development.AI Generated. May Contain Errors. Read More Receive PHGUF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Pharming Group and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PHGUF Stock News HeadlinesPharming Group: Viable Contrarian Buy If Ruconest StabilizesSeptember 30 at 8:31 AM | seekingalpha.comPharming Wins FDA Priority Review for Lower-Dose Joenja in Younger APDS PatientsSeptember 25, 2026 | tipranks.comA “bloodbath” Is ComingReports suggest some Silicon Valley billionaires are stockpiling gold, guns, and gas masks - or leaving the country entirely - as concerns grow about the next phase of the AI market. One AI insider says investors should reassess their positions before October 31, pointing to a critical shift ahead for tech and AI-related stocks.October 2 at 1:00 AM | TradeSmith (Ad)Pharming posts positive Phase II data for leniolisib in rare immune disordersSeptember 22, 2026 | tipranks.comPharming wins FDA nod to extend Joenja use to younger APDS childrenSeptember 11, 2026 | tipranks.comPharming Group Steps Up Investor Outreach With September Conference LineupSeptember 9, 2026 | tipranks.comPharming launches Joenja in Japan, first market to treat APDS children from age fourAugust 13, 2026 | tipranks.comPharming Group to Present at Canaccord Genuity Growth ConferenceAugust 4, 2026 | tipranks.comSee More Headlines PHGUF Stock Analysis - Frequently Asked Questions How have PHGUF shares performed this year? Pharming Group's stock was trading at $1.65 at the start of the year. Since then, PHGUF shares have decreased by 33.0% and is now trading at $1.1050. How were Pharming Group's earnings last quarter? Pharming Group NV (OTCMKTS:PHGUF) posted its earnings results on Thursday, May, 7th. The biotechnology company reported ($0.01) EPS for the quarter, missing the consensus estimate of $0.00 by $0.01. The biotechnology company earned $72.45 million during the quarter, compared to analyst estimates of $92.06 million. Pharming Group had a net margin of 2.51% and a trailing twelve-month return on equity of 3.40%. How do I buy shares of Pharming Group? Shares of PHGUF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings5/07/2026Today10/02/2026Next Earnings (Estimated)11/05/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolOTCMKTS:PHGUF Previous SymbolOTC:PHGUF CIKN/A Webwww.pharming.com Phone(171) 524-7400Fax31-0-71-524-7445Employees407Year Founded1988Profitability EPS (Trailing Twelve Months)$0.01 Trailing P/E Ratio92.08 Forward P/E RatioN/A P/E GrowthN/ANet Income$2.85 million Net Margins2.51% Pretax Margin4.31% Return on Equity3.40% Return on Assets1.90% Debt Debt-to-Equity Ratio0.39 Current Ratio3.01 Quick Ratio2.31 Sales & Book Value Annual Sales$376.13 million Price / Sales1.97 Cash Flow$0.02 per share Price / Cash Flow52.72 Book Value$0.41 per share Price / Book2.70Miscellaneous Outstanding Shares671,073,000Free FloatN/AMarket Cap$741.54 million OptionableNot Optionable Beta0.46 Social Links 7 Stocks That Could Lead the Next Market BoomTesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.Get This Free Report This page (OTCMKTS:PHGUF) was last updated on 10/2/2026 by MarketBeat.com Staff. From Our PartnersElon Warns "America Will Go Bankrupt". Trump's Plan Inside.National debt just crossed 40 trillion dollars, and Elon Musk says America is 1,000% going to go bankrupt with...American Hartford Gold | SponsoredMILLIONAIRE MASTERCLASS INVITE: AltucherJames Altucher says Elon Musk is preparing an unprecedented project set to surface on December 8th. Altuche...Paradigm Press | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredA new kind of civil war is coming after election day?Across America, AI-driven backlash is fueling protests, lawsuits, and moratoria that could reshape the politic...Stansberry Research | SponsoredHow Elon’s Empire Ends (and how to profit)Marc Chaikin, the 60 year Wall Street veteran whose Chaikin Money Flow indicator sits on every Bloomberg termi...Chaikin Analytics | SponsoredHow options let you do more with less capitalWould you rather spend $5,000 buying 100 shares of a $50 stock, or control those same 100 shares for a fractio...Base Camp Trading | SponsoredMajor Buy Alert Issued for October 31stKeith Kaplan has invested $17 million into his own AI research tools, building a platform now used by 180,000 ...TradeSmith | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pharming Group NV Please log in to your account or sign up in order to add this asset to your watchlist. Share Pharming Group With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
